BRAF and PIK3CA genes are somatically mutated in hepatocellular carcinoma among patients from South Italy.
about
The genetic and epigenetic alterations in human hepatocellular carcinoma: a recent updateClinical implications of BRAF mutation test in colorectal cancer.Discrepant alterations in main candidate genes among multiple primary melanomasMutation analysis of key genes in RAS/RAF and PI3K/PTEN pathways in Chinese patients with hepatocellular carcinoma.Paracrine factors of human fetal MSCs inhibit liver cancer growth through reduced activation of IGF-1R/PI3K/Akt signalingExtracellular signal-regulated kinase 1 and 2 in cancer therapy: a focus on hepatocellular carcinoma.Efficacy of sorafenib in BRAF-mutated non-small-cell lung cancer (NSCLC) and no response in synchronous BRAF wild type-hepatocellular carcinoma: a case report.Decreased expression of zinc-alpha2-glycoprotein in hepatocellular carcinoma associates with poor prognosisPrevalence of K-Ras mutations in hepatocellular carcinoma: A Turkish Oncology Group pilot study.The MAPK MEK1/2-ERK1/2 Pathway and Its Implication in Hepatocyte Cell Cycle Control.NF-κB is activated in response to temozolomide in an AKT-dependent manner and confers protection against the growth suppressive effect of the drug.Lentiviral vector-based insertional mutagenesis identifies genes associated with liver cancer.PIK3CA mutations in hepatocellular carcinoma in Korea.Increased expression of urotensin II is associated with poor prognosis in hepatocellular carcinomaTargeting the protein-protein interaction between IRS1 and mutant p110α for cancer therapy.The Complex Relationship between Liver Cancer and the Cell Cycle: A Story of Multiple Regulations.Effects of Mutations of 3 Amino Acids on Hepatocellular Carcinoma: A Systematic Review and Meta-analysis.Splicing factor hnRNP A2 activates the Ras-MAPK-ERK pathway by controlling A-Raf splicing in hepatocellular carcinoma developmentDownregulation of miR-329 promotes cell invasion by regulating BRD4 and predicts poor prognosis in hepatocellular carcinoma.Nogo-C contributes to HCC tumorigenesis via suppressing cell growth and its interactome analysis with comparative proteomics research.Evaluation of selenite effects on selenoproteins and cytokinome in human hepatoma cell lines.Targeting the Ras/Raf/MEK/ERK pathway in hepatocellular carcinoma.HBV regulated RhoC expression in HepG2.2.15 cells by enhancing its promoter activity.Frequency of BRAF V600E mutations in 969 central nervous system neoplasms.Prognostic value of BRAF V600E mutation and microsatellite instability in Japanese patients with sporadic colorectal cancer.Molecular mechanisms governing microRNA-125a expression in human hepatocellular carcinoma cells.Clinicopathological characteristics of PIK3CA and HBx mutations in Korean patients with hepatocellular carcinomas.Effects of AFP-activated PI3K/Akt signaling pathway on cell proliferation of liver cancer.A large-scale RNAi screen identifies LCMR1 as a critical regulator of Tspan8-mediated melanoma invasion.Mps1 is associated with the BRAFV600E mutation but does not rely on the classic RAS/RAF/MEK/ERK signaling pathway in thyroid carcinoma.
P2860
Q27003050-EA72697A-BF69-41DE-A6D1-CB1E486954E6Q27692120-5844E712-710E-4AD4-885D-E76AF0AC2C31Q30578299-9F02A06E-7E83-4B6F-8715-FA162243E74EQ33968053-3FA7214A-144F-4FEA-BABF-00D7E00FADFEQ35399206-2AFE7C67-F616-45FA-8136-D5CD30ED79ACQ35894374-569B2D92-41B7-4BC2-846B-6C515F8EE42EQ36070099-BF48F124-E52D-4570-A190-CA6E9F20BD6EQ36334864-82DFBA04-F58D-443D-AE98-13D31B2C54BAQ36335286-4B607C41-47C4-4291-B4EF-539E2BEEB279Q36362544-0C5DF05F-9505-461D-9BE3-68B67D866C9FQ36552658-DFB1D878-C9FF-4E5B-B594-32D3D3AD8938Q36660711-1399E37B-D3CF-474E-B094-0E04D634731AQ36872852-F204F017-C8EC-492D-B0B8-3CAE63C52B17Q37582059-323D5006-A007-4522-B737-07347A989B74Q38157714-A83B40EC-C091-43F0-B198-4FF0F0B40D50Q38178032-22C03B08-82B0-4921-A475-ECFBB8A4946BQ38254776-F99B8502-DD03-4DC5-BFBD-8CEE84EAC2ECQ38487106-59B144D5-765E-45C9-A941-563148A50036Q38828743-3F821C6A-268B-4876-A434-17B0DF05C824Q38981142-CD1EAF3A-8225-4F93-947A-F04883E94D54Q39188309-B7EA9FF1-F2C5-4D18-8FFC-412F46BF3807Q39270291-6359BB2E-54B2-4E2E-AFA5-F94339A1748CQ39324518-78294B15-05CF-427A-BDCF-7455ADA2D27EQ39650208-6CAAB985-7A9B-46DD-A086-60E939753C27Q40564690-4FAD8C1F-7746-4D62-8344-258666DF8CF4Q41629213-7707EEAC-B407-4D62-8A82-B7A3B8478A38Q42228738-44233734-C520-4E01-8865-A27E2C89A475Q42243330-0C84FF68-9ABF-4F6B-B7C2-43D5E4C06459Q51665583-7C791153-4675-42B4-B483-1B5077C00768Q54977969-7FF21712-115D-4671-A680-10AAD7F53221
P2860
BRAF and PIK3CA genes are somatically mutated in hepatocellular carcinoma among patients from South Italy.
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
2012年论文
@zh
2012年论文
@zh-cn
name
BRAF and PIK3CA genes are soma ...... ong patients from South Italy.
@ast
BRAF and PIK3CA genes are soma ...... ong patients from South Italy.
@en
type
label
BRAF and PIK3CA genes are soma ...... ong patients from South Italy.
@ast
BRAF and PIK3CA genes are soma ...... ong patients from South Italy.
@en
prefLabel
BRAF and PIK3CA genes are soma ...... ong patients from South Italy.
@ast
BRAF and PIK3CA genes are soma ...... ong patients from South Italy.
@en
P2093
P2860
P50
P356
P1476
BRAF and PIK3CA genes are soma ...... ong patients from South Italy.
@en
P2093
A Abbruzzese
A Lombardi
F Tatangelo
I Sordelli
L Tarantino
M Colombino
P Sperlongano
P2860
P2888
P356
10.1038/CDDIS.2011.136
P577
2012-01-19T00:00:00Z
P5875
P6179
1051050600